Atorvastatin ± Aspirin in Lynch Syndrome Syndrome

Launched by FOX CHASE CANCER CENTER · May 6, 2020

Keywords

ClinConnect Summary

This clinical trial is studying whether a common medication called atorvastatin, which is usually used to lower cholesterol, can help reduce the risk of colorectal cancer in people with Lynch syndrome. The researchers are also looking at whether taking atorvastatin together with aspirin, a common pain reliever, would be even more effective. Lynch syndrome is a genetic condition that increases the risk of certain cancers, including colorectal cancer.

To participate in this study, individuals need to be at least 18 years old and have a confirmed diagnosis of Lynch syndrome through genetic testing. They should also have a history of colorectal cancer that has been treated and cured for over a year. Participants will be monitored throughout the trial, and they will be required to read and sign consent documents in English. It's important to note that those with active cancer, pregnant or breastfeeding women, or individuals who cannot take these medications for health reasons cannot join the study. This trial is currently recruiting participants, and it offers a chance to contribute to important research that could help others at risk for colorectal cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects who are 18 years of age or older
• • Able to read and sign an informed consent document in English
• • Eligible subjects will have molecular evidence of Lynch Syndrome (mutation in MLH1, MSH2, MSH6, EPCAM or PMS2)
• • History of colorectal cancer if surgically cured and \> 1 year from completion of adjuvant chemotherapy
• Exclusion Criteria:
• • Are \<18 years of age
• • Unable to read and sign an informed consent document in English
• • Have active cancer or are less than 3 years post hormonal maintenance therapy for cancer
• • Have statin intolerance or contraindication for aspirin or atorvastatin use
• • Are pregnant or are actively breast feeding